Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2017

01-11-2017 | Original Article

Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma

Authors: Shih-Ping Cheng, Ming-Jen Chen, Ming-Nan Chien, Chi-Hsin Lin, Jie-Jen Lee, Chien-Liang Liu

Published in: Clinical and Experimental Medicine | Issue 4/2017

Login to get access

Abstract

Although papillary thyroid cancer is a relatively indolent malignancy, its progression may be associated with dedifferentiation and resistance to radioactive iodine treatment. In this study, patterns of differentially expressed genes in association with disease progression were systemically evaluated. We firstly performed transcriptome analyses for four matched cancerous and noncancerous tissue pairs of the classical subtype of papillary thyroid cancer. Among the upregulated and downregulated genes, the expression of 164 and 183 genes increased and decreased, respectively, from stage I to stage IV. Functional enrichment and pathway analysis showed that angiogenesis pathway was upregulated, whereas oxidation–reduction and metabolism of reactive oxygen species were downregulated. Teneurin transmembrane protein 1 (TENM1) expression was highly upregulated in cancerous tissues and negative in benign thyroid tissues. By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p < 0.001), and an advanced stage (p = 0.019). Taken together, our results indicate that distinct pathways are involved in papillary thyroid cancer progression, and TENM1 is a potential marker of cancer progression.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48–56.CrossRefPubMed Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48–56.CrossRefPubMed
4.
go back to reference Pak K, Suh S, Kim SJ, Kim IJ. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid. 2015;25:63–70.CrossRefPubMed Pak K, Suh S, Kim SJ, Kim IJ. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid. 2015;25:63–70.CrossRefPubMed
5.
go back to reference Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015;262:519–25.CrossRefPubMedPubMedCentral Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015;262:519–25.CrossRefPubMedPubMedCentral
6.
go back to reference Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559–70.CrossRefPubMedPubMedCentral Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559–70.CrossRefPubMedPubMedCentral
7.
go back to reference Cheng SP, Hsu YC, Liu CL, et al. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol. 2014;21(Suppl 4):S619–26.CrossRefPubMed Cheng SP, Hsu YC, Liu CL, et al. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol. 2014;21(Suppl 4):S619–26.CrossRefPubMed
8.
go back to reference Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simoes M. Prognostic biomarkers in thyroid cancer. Virchows Arch. 2014;464:333–46.CrossRefPubMed Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simoes M. Prognostic biomarkers in thyroid cancer. Virchows Arch. 2014;464:333–46.CrossRefPubMed
9.
go back to reference Montero-Conde C, Martin-Campos JM, Lerma E, et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene. 2008;27:1554–61.CrossRefPubMed Montero-Conde C, Martin-Campos JM, Lerma E, et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene. 2008;27:1554–61.CrossRefPubMed
10.
go back to reference Nilubol N, Sukchotrat C, Zhang L, He M, Kebebew E. Molecular pathways associated with mortality in papillary thyroid cancer. Surgery. 2011;150:1023–31.CrossRefPubMedPubMedCentral Nilubol N, Sukchotrat C, Zhang L, He M, Kebebew E. Molecular pathways associated with mortality in papillary thyroid cancer. Surgery. 2011;150:1023–31.CrossRefPubMedPubMedCentral
12.
go back to reference Smallridge RC, Chindris AM, Asmann YW, et al. RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99:E338–47.CrossRefPubMed Smallridge RC, Chindris AM, Asmann YW, et al. RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99:E338–47.CrossRefPubMed
13.
go back to reference Li R, Yu C, Li Y, et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics. 2009;25:1966–7.CrossRefPubMed Li R, Yu C, Li Y, et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics. 2009;25:1966–7.CrossRefPubMed
14.
go back to reference Chang YC, Hsu YC, Liu CL, Huang SY, Hu MC, Cheng SP. Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. PLoS ONE. 2014;9:e89563.CrossRefPubMedPubMedCentral Chang YC, Hsu YC, Liu CL, Huang SY, Hu MC, Cheng SP. Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. PLoS ONE. 2014;9:e89563.CrossRefPubMedPubMedCentral
15.
go back to reference Lee F, Lee JJ, Jan WC, Wu CJ, Chen HH, Cheng SP. Molecular pathways associated with transcriptional alterations in hyperparathyroidism. Oncol Lett. 2016;12:621–6.PubMedPubMedCentral Lee F, Lee JJ, Jan WC, Wu CJ, Chen HH, Cheng SP. Molecular pathways associated with transcriptional alterations in hyperparathyroidism. Oncol Lett. 2016;12:621–6.PubMedPubMedCentral
16.
go back to reference Wang TY, Liu CL, Chen MJ, Lee JJ, Pun PC, Cheng SP. Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer. Histopathology. 2015;66:447–56.CrossRefPubMed Wang TY, Liu CL, Chen MJ, Lee JJ, Pun PC, Cheng SP. Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer. Histopathology. 2015;66:447–56.CrossRefPubMed
17.
go back to reference Cheng SP, Liu CL, Chen MJ, et al. CD74 expression and its therapeutic potential in thyroid carcinoma. Endocr Relat Cancer. 2015;22:179–90.CrossRefPubMed Cheng SP, Liu CL, Chen MJ, et al. CD74 expression and its therapeutic potential in thyroid carcinoma. Endocr Relat Cancer. 2015;22:179–90.CrossRefPubMed
18.
go back to reference Cheng SP, Yang PS, Chien MN, Chen MJ, Lee JJ, Liu CL. Aberrant expression of tumor-associated carbohydrate antigen Globo H in thyroid carcinoma. J Surg Oncol. 2016;114:853–8.CrossRefPubMed Cheng SP, Yang PS, Chien MN, Chen MJ, Lee JJ, Liu CL. Aberrant expression of tumor-associated carbohydrate antigen Globo H in thyroid carcinoma. J Surg Oncol. 2016;114:853–8.CrossRefPubMed
19.
go back to reference Hsu YC, Liu CL, Yang PS, Tsai CH, Lee JJ, Cheng SP. Interaction of age at diagnosis with transcriptional profiling in papillary thyroid cancer. World J Surg. 2016;40:2922–9.CrossRefPubMed Hsu YC, Liu CL, Yang PS, Tsai CH, Lee JJ, Cheng SP. Interaction of age at diagnosis with transcriptional profiling in papillary thyroid cancer. World J Surg. 2016;40:2922–9.CrossRefPubMed
20.
go back to reference Rossing M. Classification of follicular cell-derived thyroid cancer by global RNA profiling. J Mol Endocrinol. 2013;50:R39–51.CrossRefPubMed Rossing M. Classification of follicular cell-derived thyroid cancer by global RNA profiling. J Mol Endocrinol. 2013;50:R39–51.CrossRefPubMed
21.
go back to reference Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 2010;322:8–28.CrossRefPubMed Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 2010;322:8–28.CrossRefPubMed
22.
23.
go back to reference Pita JM, Banito A, Cavaco BM, Leite V. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer. 2009;101:1782–91.CrossRefPubMedPubMedCentral Pita JM, Banito A, Cavaco BM, Leite V. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer. 2009;101:1782–91.CrossRefPubMedPubMedCentral
24.
go back to reference Mitchell JC, Parangi S. Angiogenesis in benign and malignant thyroid disease. Thyroid. 2005;15:494–510.CrossRefPubMed Mitchell JC, Parangi S. Angiogenesis in benign and malignant thyroid disease. Thyroid. 2005;15:494–510.CrossRefPubMed
26.
go back to reference Wang D, Feng JF, Zeng P, Yang YH, Luo J, Yang YW. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocr Relat Cancer. 2011;18:773–82.CrossRefPubMedPubMedCentral Wang D, Feng JF, Zeng P, Yang YH, Luo J, Yang YW. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocr Relat Cancer. 2011;18:773–82.CrossRefPubMedPubMedCentral
27.
go back to reference Tabur S, Aksoy SN, Korkmaz H, Ozkaya M, Aksoy N, Akarsu E. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma. Tumour Biol. 2015;36:2667–74.CrossRefPubMed Tabur S, Aksoy SN, Korkmaz H, Ozkaya M, Aksoy N, Akarsu E. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma. Tumour Biol. 2015;36:2667–74.CrossRefPubMed
28.
go back to reference Tucker RP, Chiquet-Ehrismann R. Teneurins: a conserved family of transmembrane proteins involved in intercellular signaling during development. Dev Biol. 2006;290:237–45.CrossRefPubMed Tucker RP, Chiquet-Ehrismann R. Teneurins: a conserved family of transmembrane proteins involved in intercellular signaling during development. Dev Biol. 2006;290:237–45.CrossRefPubMed
29.
go back to reference Ziegler A, Corvalan A, Roa I, Branes JA, Wollscheid B. Teneurin protein family: an emerging role in human tumorigenesis and drug resistance. Cancer Lett. 2012;326:1–7.CrossRefPubMed Ziegler A, Corvalan A, Roa I, Branes JA, Wollscheid B. Teneurin protein family: an emerging role in human tumorigenesis and drug resistance. Cancer Lett. 2012;326:1–7.CrossRefPubMed
30.
go back to reference Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044–9.CrossRefPubMedPubMedCentral Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044–9.CrossRefPubMedPubMedCentral
31.
go back to reference Nikolova DN, Zembutsu H, Sechanov T, et al. Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep. 2008;20:105–21.PubMed Nikolova DN, Zembutsu H, Sechanov T, et al. Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep. 2008;20:105–21.PubMed
32.
go back to reference Scholer J, Ferralli J, Thiry S, Chiquet-Ehrismann R. The intracellular domain of teneurin-1 induces the activity of microphthalmia-associated transcription factor (MITF) by binding to transcriptional repressor HINT1. J Biol Chem. 2015;290:8154–65.CrossRefPubMedPubMedCentral Scholer J, Ferralli J, Thiry S, Chiquet-Ehrismann R. The intracellular domain of teneurin-1 induces the activity of microphthalmia-associated transcription factor (MITF) by binding to transcriptional repressor HINT1. J Biol Chem. 2015;290:8154–65.CrossRefPubMedPubMedCentral
33.
go back to reference Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci. 2015;72:1249–60.CrossRefPubMed Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci. 2015;72:1249–60.CrossRefPubMed
34.
go back to reference Wellbrock C, Arozarena I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res. 2015;28:390–406.CrossRefPubMedPubMedCentral Wellbrock C, Arozarena I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res. 2015;28:390–406.CrossRefPubMedPubMedCentral
Metadata
Title
Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma
Authors
Shih-Ping Cheng
Ming-Jen Chen
Ming-Nan Chien
Chi-Hsin Lin
Jie-Jen Lee
Chien-Liang Liu
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2017
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-016-0445-y

Other articles of this Issue 4/2017

Clinical and Experimental Medicine 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.